Bisphosphonates: Pharmacology and Use in the Treatment of Osteoporosis

Osteoporosis: Fourth Edition

Volumn , Issue , 2013, Pages 1859-1872

  Diab, Dima L ^a   Watts, Nelson B ^b   Miller, Paul D ^c  

^a UNIVERSITY OF CINCINNATI   (United States)

^b Mercy Health Osteoporosis and Bone Health Services   (United States)

^c University of Colorado Health Sciences Center   (United States)

Author keywords

Aminobisphosphonates; Bisphosphonates; FLEX; Safety

Indexed keywords

EID: 84903056810     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-415853-5.00080-7     Document Type: Chapter

References (159)

1. Fleisch H., Neuman W.F. Mechanisms of calcification: role of collagen, polyphosphates and phosphatase. Am J Physiol 1961, 200:1296-1300.
2. Russell R.G., Watts N.B., Ebetino F.H., Rogers M.J. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008, 19:733-759.
3. Papapoulos S.E. Pharmacodynamics of bisphosphonates in man: implications for treatment. Therapy in Acute and Chronic Bone Loss 1995, 231-263. Elsevier Science, Amsterdam. O.L.M. Bijvoet, H. Fleisch, R.E. Canfield, R.G.G. Russell (Eds.).
4. Papapoulos S.E. Bisphosphonates: pharmacology and use in the treatment of osteoporosis. Osteoporosis 1996, 1209-1234. Academic Press, Philadelphia, PA. M.R. Feldman, D. Nelson, C. Rosen (Eds.).
5. Kline W.F., Matuszewski B.K. Improved determination of the bisphosphonate alendronate in human plasma and urine by automated precouumn derivatization and high performance liquid chromatography with fluorescence and electrochemical detection. J Chromotogr 1992, 583:183-193.
6. Fogelman I., Smith L., Mazess R., Wilson M.A., Bevaj J.A. Absorption of oral disphosphonate in normal subjects. Clin Endocrinol 1986, 24:57-62.
7. Gertz B.J., Holland S.D., Kline W.F., Matuszwski B.K., Freeman A., Quan H. Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther 1995, 58:288-298.
8. Miller P.D., Hochberg M.C., Wehren L.E., Ross P.D., Wasnich R.D. How useful are measures of BMD and bone turnover?. Curr Med Res Opin 2005, 21(4):545-553.
9. Miller P.D. Bone density and markers of bone turnover in predicting fracture risk and how changes in these measures predict fracture risk reduction. Curr Osteoporos Rep 2005, 3(3):103-110.
10. Bonnick S.L., Shulman L. Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both?. Am J Med 2006, 119:S25-S31.
11. Vasikaran S., Eastell R., Bruyère O., Foldes A.J., Garnero P., Griesmacher A., et al. IOF-IFCC Bone Marker Standards Working Group. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int 2011, 22:391-420.
12. Bauaer D., Krege J., Lane N., Leary E., Libanati C., Miller P., et al. National Bone Health Alliance Bone Turnover Marker Project: current practices and the need for US harmonization, standardization, and common reference ranges. Osteoporos Int 2012, 23(10):2425-2433.
13. Fleisch H., Russell R.G., Francis M.D. Disphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vitro. Science 1969, 165:1262-1264.
14. Russell R.G., Muhlbauer R.C., Bisaz S., Williams D.A., Fleisch H. The influence of pyrophosphate, condensed phosphates, phosphonates and other phosphate compounds on the dissolution of hydroxyapatite in vitro and on bone resorption induced by parathyroid hormone in tissue culture and in thyroparathyroidectomized rats. Calcif Tissue Res 1970, 6:183-189.
15. Bassett C.A.L., Donath A., Macagno F., Preisig R., Fleisch H., Frances M.D. Diphosphonates in the treatment of myositis ossificans. Lancet 1969, 7625:845.
16. Schenk R., Merz W.A., Muhlbauer R., Russell R.G., Fleisch H. Effect of ethane-1-hydroxy-1,1-disphosphonate (EHDP) and dichloromethylene diphosphonate (Cl2MDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis of rats. Calcif Tissue Res 1973, 11:196-214.
17. Lin J.H. Bisphosphonates: a review of their pharmacological properties. Bone 1996, 18:75-85.
18. Russell R.G.G., Rogers M. Bisphosphonates: from the laboratory to the clinic and back again. Bone 1999, 25:97-106.
19. Rogers M. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 2003, 9:2643-2658.
20. Ebetino F.H., Dansereau S.M. Bisphosphonate anti- resorptive structure activity relationships. Bisphosphonates in Bone 1995, 139-153. Elsevier Science, Amsterdam. O.L.M. Bijvoet, H. Fleisch, R.E. Canfield, R.G.G. Russell (Eds.).
21. Bauss F., Russell R.G.G. Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing. Osteoporos Int 2004, 15:423-433.
22. Nancollas G.H., Tang R., Phipps R.J., Henneman Z., Gulde S., Wu W., et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 2006, 38:617-627.
23. Bergstrom J.D., Bostedor R.G., Masarachia P.J., Reszka A.A., Rodan G. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys 2000, 373(1):231-241.
24. Dunford J.E., Thompson K., Coxon F.P., Luckman S.P., Hahn F.M., Poulter C.D., et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthetase in vitro and inhibition of bone resorption in vivo by nitrogen containing bisphosphonates. J Pharmacol Exp Ther 2001, 296:235-242.
25. van Beek E.R., Cohen L.H., Leroy I.M., Ebetino F.H., Lowik C.W., et al. Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates. Bone 2003, 33(5):805-811.
26. Green J.R. Chemical and biological prerequisites for novel bisphosphonate molecules: results of comparative preclinical studies. Semin Oncol 2001, 28(2 Suppl. 6):4-10.
27. Rondeau J.M., Bitsch F., Bourgier E., Geiser M., Hemmig R., Kroemer M., et al. Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs. Chem Med Chem 2006, 1(2):267-273.
28. Dunford J.E., Rohers M.J., Ebetino F.H., Phipps R.J., Coxon F.P. Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases. J Bone Miner Res 2006, 21:684-694.
29. Plotkin L.I., Manolagas S.C., Bellido T. Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts/osteocytes with novel analogs. Bone 2006, 39:443-452.
30. Dobnig H., Hofbauer L.C., Viereck V., Obermayer-Pietsch B., Fahrleitner-Pammer A. Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients. Osteoporos Int 2006, 17(5):693-703.
31. Monkkonen H., Auriola S., Lehenkari P., Kellinsalmi M., Hassinen I.E., Vepsalainen J., et al. A new endogenous ATP analogue (APPPI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by the nitrogen-containing bisphosphonates. Br J Pharmacol 2006, 147:437-445.
32. Miller P.D. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy. Clin Ther 2005, 27(4):1-16.
33. Mitchell D.Y., Barr W.H., Eusebio R.A., Stevens K.A., Duke F.P., Russell D.A., et al. Risedronate pharmacokinetics and intra- and inter-subject variability upon single dose intravenous and oral administration. Pharm Res 2001, 18:166-170.
34. Kahn S.A., Kanis J.A., Vasikaran S., Kline W.F., Matuszewski B.K., McCloskey E.V., et al. Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Miner Res 1997, 12:1700-1707.
35. Chen T., Berenson J., Vescio R., Swift R., Gilchick A., Goodin S., et al. Pharmacokinetics and pharmacodynamics of zolendronic acid in cancer patients with bone metastases. J Clin Pharmacol 2002, 42:1228-1236.
36. Phipps R., Christiansen C., Phipps R., Burgio D., Sun L., Russell D., et al. Comparison of risedronate and alendronate pharmacokinetics at clinical doses. Osteoporos Int 2003, 14:S38.
37. Lasseter K.C., Porras A.G., Denker A., Santhanagopal A., Daifotis A. Pharmacokinetic considerations in determining the terminal elimination half-lives of bisphosphonates. Clin Drug Invest 2005, 25:107-114.
38. Mitchell D.Y., Eusebio R.A., Sacco-Gibson N.A., Pallone K.A., Kelly S.C., Nesbitt J.D., et al. Dose-proportional pharmacokinetics of risedronate on single-dose oral administration to healthy volunteers. J Clin Pharmacol 2000, 40:258-265.
39. Rosen C.J., Hochberg M., Bonnick S., McClung M.R., Miller P., Broy S., et al. Treatment with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized, double-blind study. J Bone Miner Res 2005, 20:141-151.
40. Bonnick S., Saag K.G., Kiel D.P., Hochberg M., McClung M., Burnett S.A., et al. Once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg for the treatment of postmenopausal osteoporosis: 2-year results of the Fosamax Actonel Comparison Trial (FACT). J Clin Endocrinol Metab 2006, 91(7):2631-2637.
41. Porras A.G., Holland S.D., Gertz B.J. Pharmacokinetics of alendronate. Drug Disposition 1999, 36(5):315-328.
42. Roelofs A.J., Coxon F.P., Ebetino F.H., Lundy M.W., Henneman Z.J., Nancollas G.H., et al. Fluorescent risedronate analogues reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo. J Bone Miner Res 2010, 25(3):606-616.
43. Roelofs A.J., Stewart C.A., Sun S., Błazewska K.M., Kashemirov B.A., McKenna C.E., et al. Influence of bone affinity on the skeletal distribution of fluorescently labeled bisphosphonates in vivo. J Bone Miner Res 2012, 27(4):835-847.
44. Turek J., Ebetino F.H., Lundy M.W., Sun S., Kashemirov B.A., McKenna C.E., et al. Bisphosphonate binding affinity affects drug distribution in both intracortical and trabecular bone of rabbits. Calcif Tissue Int 2012, 90(3):202-210.
45. Ensrud K.E., Barrett-Conner E., Schwartz A., Santora A.C., Bauer D.C., Suryawanshi S., et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. J Bone Miner Res 2004, 19(8):1259-1269.
46. Black D.M., Schwartz A.V., Ensrud K.E., Cauley J.A., Levis S., Quandt S.A., et al. FLEX Research Group, Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006, 296:2927-2938.
47. Black D.M., Cummings S.R., Karpf D.B., Cauley J.A., Thompson D.E., Nevitt M.C., et al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996, 348:1535-1541.
48. Cummings S.R., Black D.M., Thompson D.E., Applegate W.B., Barrett-Connor E., Musliner T.A., et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998, 280:2077-2082.
49. Harris S.T., Watts N.B., Genant H.K., McKeever C.D., Hangartner T., Keller M., et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 1999, 282:1344-1352.
50. Reginster J.-Y., Minne H., Sorenson O.H., Hooper M., Roux C., Brandi M.L., et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000, 11:83-91.
51. Chesnut C.H., Skag A., Christiansen C., Recker R., Stakkestad J.A., Hoiseth A., et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004, 19:1241-1249.
52. Black D.M., Delmas P.D., Eastell R., Reid I.R., Boonen S., Cauley J.A., et al. HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007, 356(18):1809-1822.
53. Schnitzer T., Bone H., Crepasldi G., Adami S., McClung M., Kiel D., et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging Clin Exp Res 2000, 12:1-12.
54. Brown J.P., Kendler D.L., McClung M.R., Emkey R.D., Adachi J.D., Bolognese M.A., et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 2002, 71:103-111.
55. Eisman J.A., Civitelli R., Adami S., Czerwinski E., Recknor C., Prince R., et al. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheumatol 2008, 35:488-497.
56. Pols H.A., Felsenberg D., Hanley D.A., Stepan J., Munoz-Torres M., Wilkin T.J., et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int 1999, 9:461-468.
57. McClung M.R., Geusens P., Miller P.D., Zippel H., Bensen W.G., Roux C., et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001, 344:333-340.
58. Harris S., Blumenthal W., Miller P.D. Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a metaanalysis of phase III studies. Curr Med Res Opin 2008, 24:237-245.
59. Tosteson A.N., Grove M.R., Hammond C.S., Moncur M.M., Ray G.T., Herbert G.M., et al. Early discontinuation of treatment for osteoporosis. Am J Med 2003, 115:209-216.
60. Miller N.H. Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med 1997, 102:43-49.
61. Simon J.A., Lewiecki E.M., Smith M.E., Petruschke R.A., Wang L., Palmisano J.J. Patient preference for once weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label cross-over study. Clin Ther 2002, 24:1871-1886.
62. Kendler D., Kung A.W., Gel-Fuleihan G.-H., Gonzalez J.G., Gaines K.A., Verbruggen N., et al. Patients with osteoporosis prefer once weekly to once daily dosing with alendronate. Maturitas 2004, 48:243-251.
63. Emkey R., Koltun W., Beusterien K., Seidman L., Kivitz A., Devas D., et al. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 2005, 21(12):1895-1903.
64. Emkey R.D., Ettinger M. Improving compliance and persistence with bisphosphonate therapy for osteoporosis. Am J Med 2006, 119(4 Suppl. 1):S18-S24.
65. Cramer J.A., Amontar M., Hebborn A., Suppapanya N. Assessing the relationship between bisphosphonate dosing regimen and treatment adherence among post-menopausal osteoporotic women. Arthritis Rheum 2004, 15:S6.
66. Cramer J.A., Silverman S. Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem. Am J Med 2006, 119(4 Suppl. 1):S12-S17.
67. Cramer J.A., Amoktar M.M., Hebborn A., Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005, 21(9):1453-1460.
68. Caro J.J., Isaac K.J., Huybrechts K.F., Raggio G., Naujoks C. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004, 15:1003-1008.
69. Siris E., Harris S.T., Rosen C.J., Barr C.D.E., Arvesen J.N., Abbott T.A., et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006, 81(8):1013-1022.
70. Delmas P.D., Li Z., Cooper C. Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: some issues with meta-analyses. J Bone Miner Res 2004, 19:330-337.
71. Watts N.B., Geusens P., Barton I.P., Felsenberg D. Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD. J Bone Miner Res 2005, 20:2097-2104.
72. Jacques R.M., Boonen S., Cosman F., Reid I.R., Bauer D.C., Black D.M., et al. Relationship of changes in total hip bone mineral density to vertebral and non-vertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5mg: the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 2012, 27(8):1627-1634.
73. Hochberg M., Greenspan S., Wasnich R., Miller P.D., Thompson D., Ross P. Changes in bone density and turnover explain the reductions in incidence of non-vertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 2002, 87:1586-1592.
74. Lewiecki E.M., Watts N.B. Assessing response to osteoporosis therapy. Osteoporos Int 2008, 19(10):1363-1368.
75. Watts N.B., Lewiecki E.M., Bonnick S.L., Laster A.J., Binkley N., Blank R.D., et al. Clinical value of monitoring BMD in patients treated with bisphosphonates for osteoporosis. J Bone Miner Res 2009, 24(10):1643-1646.
76. Miller P.D. Bone strength and surrogate markers: the first, second, and third fiddle. J Bone Miner Res 2012, 27(8):1623-1626.
77. Heaney R.P., Yates A.J., Santora A.V. Bisphosphonate effects and the bone remodeling transient. J Bone Miner Res 1997, 12(8):1143-1151.
78. Borah B., Dufresne T.E., Chmielewski P.A., Gross G.J., Prenger M.C., Phipps R.J. Risedronate preserves trabecular architecture and increases bone strength in vertebra of ovariectomized minipigs as measured by three-dimensional microcomputed tomography. J Bone Miner Res 2002, 17:1139-1147.
79. Diab T., Condon K.W., Burr D.B., Vashishth D. Age-related change in the damage morphology of human cortical bone and its role in bone fragility. Bone 2006, 38(3):427-431.
80. Bell K.L., Loveridge N., Power J., Garrahan N., Meggitt B.F., Reeve J. Regional differences in cortical porosity in the fractured femoral neck. Bone 1999, 24:57-64.
81. Roschger P., Rinnerthaler S., Yates J.P., Rodan G.A., Fratzl P., Klaushofer K.J., et al. Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone 2001, 29:185-191.
82. Chavassieux P.M., Arlot M.E., Reda C., Wei L., Yates A.J., Meunier P.J. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 1997, 100:1475-1480.
83. Recker R.R., Weinstein R.S., Chesnut C.H., Schimmer R.C., Mahoney P., Hughes C., et al. Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study. Osteoporos Int 2004, 15:231-237.
84. Recker R.R., Delmas P.D., Halse J., Reid I.R., Boonen S., García-Hernandez P.A., et al. Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res 2008, 23:6-16.
85. Bonnick S.L., Beck T.J., Cosman F., Hochberg M., Baran D.T., Shah A.K., et al. Comparison of the effects of alendronate vs risedronate on the structural geometry of the hip: an analysis of the US Fosamax-Actonel comparator trial. J Bone Miner Res 2006, SA345.
86. Black D.M., Reid I., Boonen S., Bucci-Rechtweg C., Cauley J.A., Cosman F., et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 2012, 27(2):243-254.
87. Whitaker M., Guo J., Kehoe T., Benson G. Bisphosphosphonates for osteoporosis-where do we go from here?. N Engl J Med 2012, 366(22):2048-2051.
88. Black D.M., Bauer D.C., Schwartz A.V., Cummings S.R., Rosen C.J. Continuing bisphosphonate treatment for osteoporosis: for whom and for how long?. N Engl J Med 2012, 366(22):2051-2053.
89. Schwartz A.V., Bauer D.C., Cummings S.R., Cauley J.A., Ensrud K.E., Palermo L., et al. Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J Bone Miner Res 2010, 25:976-982.
90. Abrahamsen B., Eiken P., Eastell R. More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009, 360(17):1789.
91. Solomon D.H., Patrick A., Brookhart M.A. More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009, 360(17):1789-1790.
92. Cardwell C.R., Abnet C.C., Cantwell M.M., Murray L.J. Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA 2010, 304:657-663.
93. Green J., Czanner G., Reeves G., Watson J., Wise L., Beral V. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ 2010, 341:c4444.
94. Wysowski D.K., Chang J.T. Alendronate and risedronate: reports of severe bone, joint, and muscle pain. Arch Intern Med 2005, 165:346-347.
95. Adami S., Bhalla A.K., Dorizzi R., Montesanti F., Rosini S., Salvagno G., et al. The acute phase response after bisphosphonate administration. Calcif Tissue Int 1987, 41:326-331.
96. Gallacher S.J., Ralston S.H., Patel U., Boyle I.T. Side-effects of pamidronate. Lancet 1989, 2:42-43.
97. Zojer N., Keck A.V., Pecherstorfer M. Comparative tolerability of drug therapies for hypercalcaemia of malignancy. Drug Safety 1999, 21(5):389-406.
98. Lyles K.W., Colon-Emeric C.S., Magaziner J.S., Adachi J.D., Pieper C.F., Mautalen C., et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007, 357:1799-1809.
99. Cummings S.R., Schwartz A.V., Black D.M. Alendronate and atrial fibrillation. N Engl J Med 2007, 356:1895-1896.
100. Karam R., Camm J., McClung M. Yearly zoledronic acid in postmenopausal osteoporosis. N Engl J Med 2007, 357:712-713.
101. Lewiecki E.M., Cooper C., Thompson E., Hartl F., Mehta D., Papapoulos S.E. Ibandronate does not increase risk of atrial fibrillation in analysis of pivotal clinical trials. Int J Clin Pract 2010, 64(6):821-826.
102. Heckbert S.R., Li G., Cummings S.R., Smith N.L., Psaty B.M. Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med 2008, 168:826-831.
103. Sorensen H.T., Christensen S., Mehnert F., Pedersen L., Chapurlat R.D., Cummings S.R., et al. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ 2008, 336:813-816.
104. Abrahamsen B., Eiken P., Brixen K. Atrial fibrillation in fracture patients treated with oral bisphosphonates. J Intern Med 2009, 265:581-592.
105. Bunch T.J., Anderson J.L., May H.T., Muhlestein J.B., Horne B.D., Crandall B.G., et al. Relation of bisphosphonate therapies and risk of developing atrial fibrillation. Am J Cardiol 2009, 103:824-828.
106. Grosso A., Douglas I., Hingorani A., MacAllister R., Smeeth L. Oral bisphosphonates and risk of atrial fibrillation and flutter in women: a self-controlled case-series safety analysis. PLoS One 2009, 4:e4720.
107. Miller P.D., Roux C., Boonen S., Barton I.P., Dunlap L.E., Burgio D.E. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res 2005, 20:2105-2115.
108. Jamal S.A., Bauer D.C., Ensrud K.E., Cauley J.A., Hochberg M., Ishani A., et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. J Bone Miner Res 2007, 22:503-508.
109. Miller P.D. The kidney and bisphosphonates. Bone 2011, 49(1):77-81.
110. Boonen S., Sellmeyer D.E., Lippuner K., Orlov-Morozov A., Abrams K., Mesenbrink P., et al. Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney Int 2008, 74:641-648.
111. Lewiecki E.M., Miller P.D. Renal safety of intravenous bisphosphonates in the treatment of osteoporosis. Exp Opin Drug Saf 2007, 6:663-672.
112. Miller P.D., Ward P., Pfister T., Leigh C., Body J.J. Renal tolerability of intermittent intravenous ibandronate treatment for patients with postmenopausal osteoporosis: a review. Clin Exp Rheumatol 2008, 26:1125-1133.
113. Miller P.D., Ragi-Eis S., Mautalen C., Ramirez F., Jonkanski I. Effects of intravenous ibandronate injection on renal function in women with postmenopausal osteoporosis at high risk for renal disease- the DIVINE study. Bone 2011, 49(6):1317-1322.
114. Miller P.D. Diagnosis and treatment of osteoporosis in chronic renal disease. Semin Nephrol 2009, 29:144-155.
115. Miller P.D. Is there a role for bisphosphonates in chronic kidney disease?. Semin Dial 2007, 20:186-190.
116. Miller P.D. The role of bone biopsy in patients with chronic renal failure. Clin J Am Soc Nephrol 2008, 3(Suppl. 3):S140-S150.
117. Khosla S., Burr D., Cauley J., Dempster D.W., Ebeling P.R., Felsenberg D., et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007, 22:1479-1491.
118. Woo S.B., Hellstein J.W., Kalmar J.R. Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006, 206(144):753-761.
119. Treister N., Woo S.B. Bisphosphonate-associated osteonecrosis of the jaw. N Engl J Med 2006, 335:2348.
120. Bilezikian J.P. Osteonecrosis of the jaw: do bisphosphonates pose a risk?. N Engl J Med 2006, 355:2278-2282.
121. Black D.M., Boonen S., Cauley J., Delmas P., Eastell R., Reid I., et al. Effect of once-yearly infusion of zoledronic acid 5 mg on spine and hip fracture reduction in postmenopausal women with osteoporosis: the HORIZON pivotal fracture trial (abstract). J Bone Miner Res 2006, 21(Suppl. 1):S16.
122. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007, 65:369-376.
123. Hellstein J.W., Adler R.A., Edwards B., Jacobsen P.L., Kalmar J.R., Koka S., et al. Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc 2011, 142:1243-1251.
124. Kwek E.B., Goh S.K., Koh J.S., Png M.A., Howe T.S. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?. Injury 2008, 39:224-231.
125. Lee P., Seibel M.J. More on atypical fractures of the femoral diaphysis. N Engl J Med 2008, 359:317.
126. Lee P., van der Wall H., Seibel M.J. Looking beyond low bone mineral density: multiple insufficiency fractures in a woman with post-menopausal osteoporosis on alendronate therapy. J Endocrinol Invest 2007, 30:590-597.
127. Lenart B.A., Lorich D.G., Lane J.M. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 2008, 358:1304-1306.
128. Odvina C.V., Levy S., Rao S., Zerwekh J.E., Rao D.S. Unusual mid-shaft fractures during long-term bisphosphonate therapy. Clin Endocrinol (Oxf) 2010, 72:161-168.
129. Schneider J.P. Should bisphosphonates be continued indefinitely? An unusual fracture in a healthy woman on long-term alendronate. Geriatrics 2009, 61:31-33.
130. Armamento-Villareal R., Napoli N., Panwar V., Novack D. Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis. N Engl J Med 2006, 355:2048-2050.
131. Capeci C.M., Tejwani N.C. Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy. J Bone Joint Surg Am 2009, 91:2556-2561.
132. Goh S.K., Yang K.Y., Koh J.S., Wong M.K., Chua S.Y., Chua D.T., et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br 2007, 89:349-353.
133. Lenart B.A., Neviaser A.S., Lyman S., Chang C.C., Edobor-Osula F., Steele B., et al. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int 2009, 20:1353-1362.
134. Neviaser A.S., Lane J.M., Lenart B.A., Edobor-Osula F., Lorich D.G. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 2008, 22:346-350.
135. Abrahamsen B., Eiken P., Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 2009, 24:1095-1102.
136. Park-Wyllie L.Y., Mamdani M.M., Juurlink D.N., Hawker G.A., Gunraj N., Austin P.C., et al. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 2011, 305:783-789.
137. Shane E., Burr D., Ebeling P.R., Abrahamsen B., Adler R.A., Brown T.D., et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010, 25:2267-2294.
138. Paul O., Barker J.U., Lane J.M., Helfet D.L., Lorich D.G. Functional and radiographic outcomes. J Orthop Trauma 2010, 26(3):148-154.
139. Kang J.H., Keller J.J., Lin H.C. A population-based 2-year follow-up study on the relationship between bisphosphonates and the risk of stroke. Osteoporos Int 2012, 23(10):2551-2557.
140. Hartle J.E., Tang X., Kirchner H.L., Bucaloiu I.D., Sartorius J.A., Pogrebnaya Z.V., et al. Bisphosphonate therapy, death, and cardiovascular events among female patients with CKD: a retrospective cohort study. Am J Kidney Dis 2012, 59(5):636-644.
141. Center J.R., Bliuc D., Nguyen N.D., Nguyen T.V., Eisman J.A. Osteoporosis medication and reduced mortality risk in elderly women and men. J Clin Endocrinol Metab 2011, 96:1006-1014.
142. Sambrook P.N., Cameron I.D., Chen J.S., March L.M., Simpson J.M., Cumming R.G., et al. Oral bisphosphonates are associated with reduced mortality in frail older people: a prospective five-year study. Osteoporos Int 2011, 22:2551-2556.
143. Beaupre L.A., Morrish D.W., Hanley D.A., Maksymowych W.P., Bell N.R., Juby A.G., et al. Oral bisphosphonates are associated with reduced mortality after hip fracture. Osteoporos Int 2011, 22:983-991.
144. Chlebowski R.T., Col N. Bisphosphonates and breast cancer incidence and recurrence. Breast Dis 2011, 33(2):93-101.
145. Chlebowski R.T., Chen Z., Cauley J.A., Anderson G., Rodabough R.J., McTiernan A., et al. Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol 2010, 28:3582-3590.
146. Chlebowski R.T., Col N. Bisphosphonates and breast cancer prevention. Anticancer Agents Med Chem 2012, 12:144-150.
147. Dreyfuss J.H. Oral bisphosphonate use associated with a decreased risk of breast cancer. CA Cancer J Clin 2010, 60:343-344.
148. Gnant M. Can oral bisphosphonates really reduce the risk of breast cancer in healthy women?. J Clin Oncol 2010, 28:3548-3551.
149. Newcomb P.A., Trentham-Dietz A., Hampton J.M. Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk. Br J Cancer 2010, 102:799-802.
150. Rennert G., Pinchev M., Rennert H.S. Use of bisphosphonates and risk of postmenopausal breast cancer. J Clin Oncol 2010, 28:3577-3581.
151. Vestergaard P., Fischer L., Mele M., Mosekilde L., Christiansen P. Use of bisphosphonates and risk of breast cancer. Calcif Tissue Int 2011, 88:255-262.
152. Rennert G., Pinchev M., Rennert H.S., Gruber S.B. Use of bisphosphonates and reduced risk of colorectal cancer. J Clin Oncol 2011, 29:1146-1150.
153. Writing Group for the Women's Health Initiative Investigators Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002, 288:321-333.
154. Kanis J.A., Hans D., Cooper C., Baim S., Bilezikian J.P., Binkley N., et al. Interpretation and use of FRAX in clinical practice. Osteoporos Int 2011, 22(9):2395-2411.
155. Bonnick S.L. Going on a drug holiday?. J Clin Densit 2011, 14(2):1-7.
156. Boonen S., Ferrari S., Miller P.D., Eriksen E.F., Sambrook P.N., Compston J., et al. Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long term continuation on bone turnover and fracture risk-a perspective. J Bone Miner Res 2012, 27(5):963-974.
157. Watts N.B., Diab D.L. Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab 2010, 95(4):1555-1565.
158. Khosla S., Bilezikian J.P., Dempster D.W., Lewiecki E.M., Miller P.D., Neer R.M., et al. Benefits and risks of bisphosphonate therapy for osteoporosis. J Clin Endocrinol Metab 2012, 97(7):2272-2282.
159. Rogers M.J., Crockett J.C., Coxon F.P., Monkkonen J. Biochemical and molecular mechanisms of action of bisphosphonates. Bone 2011, 49(1):34-41.